Pipeline for specific subtype amplification and drug resistance detection in hepatitis c virus

[Background] Despite the high sustained virological response rates achieved with current directly-acting antiviral agents (DAAs) against hepatitis C virus (HCV), around 5–10% of treated patients do not respond to current antiviral therapies, and basal resistance to DAAs is increasingly detected amon...

ver descrição completa

Detalhes bibliográficos
Autores: Soria, María Eugenia, Gregori, Josep Maria, Chen, Qian, García-Cehic, Damir, Llorens-Revull, Meritxell, Ávila Lucas, Ana Isabel de, Beach, Nathan M., Domingo, Esteban, Rodríguez-Frías, Francisco, Buti, María, Esteban, Rafael, Esteban, Juan Ignacio, Quer, Josep, Perales, Celia
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2018
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/169488
Acesso em linha:http://hdl.handle.net/10261/169488
Access Level:acceso abierto
Palavra-chave:Next-generation sequencing
Viral quasispecies
Antiviral agents
Viral diagnostics
Treatment planning
Descrição
Resumo:[Background] Despite the high sustained virological response rates achieved with current directly-acting antiviral agents (DAAs) against hepatitis C virus (HCV), around 5–10% of treated patients do not respond to current antiviral therapies, and basal resistance to DAAs is increasingly detected among treatment-naïve infected individuals. Identification of amino acid substitutions (including those in minority variants) associated with treatment failure requires analytical designs that take into account the high diversification of HCV in more than 86 subtypes according to the ICTV website (June 2017).

Registos relacionados